A number of investment brokers have recently updated their price targets on shares of Amedisys Inc (NASDAQ:AMED). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/06/2016 – Amedisys Inc had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 48 price target on the stock.

04/11/2016 – Amedisys Inc had its “buy” rating reiterated by analysts at Mizuho. They now have a USD 57 price target on the stock.

04/05/2016 – Amedisys Inc had its “market perform” rating reiterated by analysts at Obsidian.

03/10/2016 – Amedisys Inc had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 45 price target on the stock.

01/13/2016 – Amedisys Inc had its “neutral” rating reiterated by analysts at Robert W. Baird. They now have a USD 39 price target on the stock.

01/11/2016 – Amedisys Inc had its “market perform” rating reiterated by analysts at Raymond James.

11/06/2015 – Amedisys Inc had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 45 price target on the stock.

09/01/2015 – Wells Fargo began new coverage on Amedisys Inc giving the company a “outperform” rating.

07/07/2015 – Amedisys Inc had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 44 price target on the stock.

06/19/2015 – Amedisys Inc was upgraded to “buy” by analysts at Jefferies. They now have a USD 48 price target on the stock.

06/09/2015 – Amedisys Inc was upgraded to “hold » buy” by analysts at Deutsche Bank. They now have a USD 28 price target on the stock.

05/03/2015 – Amedisys Inc had its “underperform” rating reiterated by analysts at Credit Suisse. They now have a USD 26 price target on the stock.

03/16/2015 – Amedisys Inc was downgraded to “neutral” by analysts at Zacks. They now have a USD 29 price target on the stock.

03/05/2015 – Amedisys Inc had its “market perform” rating reiterated by analysts at Avondale Partners. They now have a USD 26 price target on the stock.

06/28/2014 – Amedisys Inc was upgraded to “fair value” by analysts at CRT Capital.

The share price of Amedisys Inc (NASDAQ:AMED) was up +3.16% during the last day of trading, with a day high of 51.25. 266733 shares were traded during the last session.

The stock’s 50 day moving average is 48.62 and its 200 day moving average is 41.45. The stock’s market capitalization is 1.73B. Amedisys Inc has a 52-week low of 27.67 and a 52-week high of 54.29.

View other investors thoughts on Amedisys Inc with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.